Class action lawsuit filed against Unicycive Therapeutics over alleged securities violations

NEW YORK, Bronstein, Gewirtz & Grossman, LLC, a leading investor-rights law firm, has announced the filing of a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers. The lawsuit seeks to recover damages for alleged violations of federal securities laws on behalf of investors who purchased or otherwise acquired Unicycive securities between December 29, 2025, and June 29, 2026, inclusive.

According to the complaint, the defendants are accused of making materially false and misleading statements and failing to disclose critical information regarding Unicycive's third-party manufacturing vendor. Specifically, the lawsuit alleges that Unicycive had not inspected its vendor's facility or audited its compliance with current good manufacturing practices. Consequently, the company is said to have lacked a reasonable basis to believe that the vendor had remedied deficiencies cited by the Food and Drug Administration (FDA). The complaint further states that there was a material risk that the FDA would require additional information concerning the vendor's manufacturing practices, which could result in a delay of regulatory approval for oxylanthanum carbonate. This delay, the lawsuit claims, rendered defendants' positive statements about Unicycive's business, operations, and prospects materially false and misleading.

Bronstein, Gewirtz & Grossman, LLC encourages investors who purchased Unicycive securities during the class period to review the complaint and consider joining the case by visiting the firm’s website: <https://bgandg.com/cases/unicycive-therapeutics-inc-uncy-class_action_lawsuit>. Investors are advised to act quickly; the deadline to request appointment as lead plaintiff is November 2, 2026.

Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC, commented, "Our firm is committed to protecting the interests of investors and ensuring accountability from companies. This case highlights the importance of thorough due diligence and transparent communication in the pharmaceutical industry."

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized firm, has a track record of recovering hundreds of millions of dollars for investors nationwide. The firm represents investors in securities fraud class actions and shareholder derivative suits.